Here's the super secret confirmed source. Shhh, do
Post# of 30025
Quote:
Mr. Commissiong, continued, "We look forward to reporting data from this study before the end of the year and believe the in-depth analysis of LymPro in mild-to-severe Alzheimer's will be invaluable to the medical community, patients and their families in diagnosing the early stages of this debilitating and previously very difficult to diagnose disease. We are excited to be in the final planning stages of bringing the first commercially-viable Alzheimer's blood diagnostic to the market, and believe LymPro can play a critical role where there is a tremendous need for groundbreaking advancements."
Amarantus anticipates making LymPro available for the Investigational Use Only (IUO) market before the end of 2014. Based on the results from the initial LP-002 cohort data, Amarantus is validating both Version 1 and Version 2 of LymPro for commercialization in IUO with a primary target of pharmaceutical clinical trials. Clinical Laboratory Improvement Amendments (CLIA) certification is not required to launch LymPro in the IUO market. Following the in-depth analysis of the full 140-subject mild-to-severe AD cohort, Amarantus will then make a determination regarding which version of LymPro (Version 1 or Version 2) to launch under the CLIA designation for marketing to the broader medical community in the United States in 2015.
Shhhh, don't tell anyone their plans!
Cheers